Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 284

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 284
---

as of November 28, 2023, pursuant to which holders of the Company’s common shares received of a common share for every
common share.

All issued and outstanding common shares
or instruments convertible into common shares contained in these financial statements have been retroactively adjusted to reflect the
reverse share split for all periods presented, unless explicitly stated otherwise.

F-43 CLEARMIND MEDICINE INC. Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended July 31, 2025 and 2024 (Expressed in United States Dollars) (Unaudited)

| 2. | Material Accounting Policy Information |

| a. | Basis of Presentation |

The accompanying consolidated financial
statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International
Accounting Standards Board (“IASB”) on a going concern basis.

These condensed interim consolidated
financial statements include the accounts of the Company and its wholly-owned subsidiaries, Clearmindmed Ltd. and Clearmind Labs Corp.
(inactive). All inter-company balances and transactions have been eliminated on consolidation.

These condensed interim consolidated
financial statements have been prepared on a historical cost basis, except for financial assets and liabilities (including derivatives)
which are presented at fair value through profit or loss (“FVTPL”), and are presented in United States dollars, which is the
Company’s functional currency.

| b. | Unaudited Interim Financial Information |

Certain information and footnote disclosures
normally included in financial statements prepared in accordance with IFRS have been condensed or omitted from this report, as is permitted
by such rules and regulations. Accordingly, these condensed interim consolidated financial statements should be read in conjunction with
the audited financial statements as of and for the year ended October 31, 2024 and the notes thereto (the “2024 Annual Report”).

The condensed interim consolidated financial
statements have been prepared on the same basis as the 2024 Annual Report. In the opinion of the Company’s management, these condensed
interim consolidated financial statements contain all adjustments that are necessary to present fairly the Company’s financial position
and results of operations for the interim periods presented. The results for the nine months ended July 31, 2025 are not necessarily indicative
of the results for the year ending October 31, 2025, or for any future period.

As of July 31, 2025, there have been
no material changes in the Company’s significant accounting policies